Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
- 22 July 2002
- reference entry
- Published by Wiley
- No. 3,p. CD003427
- https://doi.org/10.1002/14651858.cd003427
Abstract
People with sickle cell disease are particularly susceptible to infection. Infants and very young children are especially vulnerable, and the Cooperative Study of Sickle Cell Disease observed an incidence rate of 10 per 100 patient years of pneumococcal septicaemia in children under the age of three. Vaccines, including customary pneumococcal vaccines, may be of limited use in this age group. Therefore, prophylactic penicillin regimes may be advisable for this population. To assess the effects of prophylactic antibiotic regimes for preventing pneumococcal infection in children with sickle cell disease. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group specialist trials register which comprises references identified from comprehensive electronic database searches, hand searching relevant journals and hand searching abstract books of conference proceedings. Date of the most recent search: December 2001. All randomised or quasi-randomised controlled trials comparing prophylactic antibiotics to prevent pneumococcal infection in children with sickle cell disease with placebo, no treatment or a comparator drug. Both reviewers independently extracted data and assessed trial quality. Five trials were identified by the initial search, of which three trials met the inclusion criteria. All of the included trials showed a reduced risk of infection in children with sickle cell disease (SS or Sb0Thal) receiving prophylactic penicillin. For initiation of treatment the odds ratio was 0.37 (95% CI 0.16, 0.86), and for withdrawal OR= 0.49 (95% CI 0.09, 2.71). Adverse drug effects were rare and minor. Rates of pneumococcal infection were found to be relatively low in children over the age of five. Prophylactic penicillin significantly reduces risk of pneumococcal infection in children with homozygous sickle cell disease, and is associated with minimal adverse reactions. Further research may help to determine the ideal age to safely withdraw penicillin.Keywords
This publication has 25 references indexed in Scilit:
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- Neonatal screening for sickle cell diseaseCochrane Database of Systematic Reviews, 2000
- Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell diseaseBritish Journal of Clinical Pharmacology, 1998
- Influence of Penicillin Prophylaxis on Antimicrobial Resistance in Nasopharyngeal S. Pneumoniae among Children with Sickle Cell AnemiaJournal of Pediatric Hematology/Oncology, 1997
- Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: Effects of continued penicillin prophylaxisThe Journal of Pediatrics, 1996
- Discontinuing penicillin prophylaxis in children with sickle cell anemiaThe Journal of Pediatrics, 1995
- Penicillin prophylaxis in children with sickle cell disease in Brent.BMJ, 1991
- Sickle cell anaemia trialStatistics in Medicine, 1990
- Prophylaxis with Oral Penicillin in Children with Sickle Cell AnemiaNew England Journal of Medicine, 1986
- Effect of penicillin prophylaxis on nasopharyngeal colonization with Streptococcus pneumoniae in children with sickle cell anemiaThe Journal of Pediatrics, 1984